Podjanee Jittamala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2883652/publications.pdf

Version: 2024-02-01

30 papers 3,545 citations

20 h-index 30 g-index

32 all docs 32 docs citations

times ranked

32

4331 citing authors

#	Article	IF	CITATIONS
1	Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Communications Biology, 2022, 5, 274.	4.4	33
2	Identification of the metabolites of ivermectin in humans. Pharmacology Research and Perspectives, 2021, 9, e00712.	2.4	21
3	A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?. PLoS Neglected Tropical Diseases, 2021, 15, e0009144.	3.0	34
4	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. ELife, $2021,10,10$	6.0	53
5	Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers. Human Vaccines and Immunotherapeutics, 2020, 16, 33-41.	3.3	9
6	Safety, Pharmacokinetics, and Mosquitoâ€Lethal Effects of Ivermectin in Combination With Dihydroartemisininâ€Piperaquine and Primaquine in Healthy Adult Thai Subjects. Clinical Pharmacology and Therapeutics, 2020, 107, 1221-1230.	4.7	30
7	Prevention of mother-to-child transmission of hepatitis B virus: protocol for a one-arm, open-label intervention study to estimate the optimal timing of tenofovir in pregnancy. BMJ Open, 2020, 10, e038123.	1.9	9
8	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet, The, 2020, 395, 1345-1360.	13.7	182
9	Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infectious Diseases, The, 2019, 19, 943-951.	9.1	219
10	Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infectious Diseases, The, 2019, 19, 952-961.	9.1	252
11	Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
12	Impact of glucose-6-phosphate dehydrogenase deficiency on dengue infection in Myanmar children. PLoS ONE, 2019, 14, e0209204.	2.5	10
13	Predicting the severity of dengue fever in children on admission based on clinical features and laboratory indicators: application of classification tree analysis. BMC Pediatrics, 2018, 18, 109.	1.7	65
14	Challenges arising when seeking broad consent for health research data sharing: a qualitative study of perspectives in Thailand. BMC Medical Ethics, 2018, 19, 86.	2.4	18
15	Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. PLoS Neglected Tropical Diseases, 2018, 12, e0006440.	3.0	45
16	Enantiospecific pharmacokinetics and drug–drug interactions of primaquine and blood-stage antimalarial drugs. Journal of Antimicrobial Chemotherapy, 2018, 73, 3102-3113.	3.0	20
17	Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis. PLoS ONE, 2018, 13, e0198695.	2.5	27
18	Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers. British Journal of Clinical Pharmacology, 2017, 83, 2752-2766.	2.4	28

#	Article	IF	CITATIONS
19	Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. New England Journal of Medicine, 2016, 375, 1152-1160.	27.0	89
20	Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and nonâ€obese volunteers. British Journal of Clinical Pharmacology, 2016, 81, 1103-1112.	2.4	19
21	Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infectious Diseases, The, 2016, 16, 576-583.	9.1	67
22	Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 61-69.	9.1	147
23	Evaluation and Acceptability of a Simplified Test of Visual Function at Birth in a Limited-Resource Setting. PLoS ONE, 2016, 11, e0157087.	2.5	1
24	Long-term impact of childhood malaria infection on school performance among school children in a malaria endemic area along the Thai–Myanmar border. Malaria Journal, 2015, 14, 401.	2.3	23
25	Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects. Antimicrobial Agents and Chemotherapy, 2015, 59, 505-513.	3.2	41
26	Spiroindolone KAE609 for Falciparum and Vivax Malaria. New England Journal of Medicine, 2014, 371, 403-410.	27.0	197
27	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. New England Journal of Medicine, 2014, 371, 411-423.	27.0	1,753
28	Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects. Antimicrobial Agents and Chemotherapy, 2014, 58, 7340-7346.	3.2	42
29	Pharmacokinetic Interactions between Primaquine and Chloroquine. Antimicrobial Agents and Chemotherapy, 2014, 58, 3354-3359.	3.2	78
30	Pharmacokinetics of Orally Administered Oseltamivir in Healthy Obese and Nonobese Thai Subjects. Antimicrobial Agents and Chemotherapy, 2014, 58, 1615-1621.	3.2	21